Public Sector Pension Investment Board Buys 4,208 Shares of Hologic, Inc. (NASDAQ:HOLX)

Public Sector Pension Investment Board lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 92.5% in the 2nd quarter, Holdings Channel reports. The fund owned 8,759 shares of the medical equipment provider’s stock after acquiring an additional 4,208 shares during the quarter. Public Sector Pension Investment Board’s holdings in Hologic were worth $650,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares during the period. Swedbank AB acquired a new position in shares of Hologic during the first quarter worth about $120,827,000. Black Creek Investment Management Inc. boosted its position in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after buying an additional 885,524 shares during the period. Cubist Systematic Strategies LLC grew its holdings in shares of Hologic by 207.9% during the fourth quarter. Cubist Systematic Strategies LLC now owns 538,814 shares of the medical equipment provider’s stock worth $38,498,000 after buying an additional 363,796 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Hologic by 18.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock valued at $170,297,000 after acquiring an additional 338,212 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $79.77 on Thursday. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The business’s 50 day moving average price is $81.22 and its two-hundred day moving average price is $77.38. The company has a market cap of $18.62 billion, a PE ratio of 40.70, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the firm earned $0.93 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. On average, analysts predict that Hologic, Inc. will post 4.09 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HOLX. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Tuesday, September 17th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. Evercore ISI increased their price objective on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and lowered their target price for the company from $95.00 to $85.00 in a research report on Tuesday. Finally, Stephens reissued an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $87.00.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock valued at $1,469,973 over the last ninety days. 1.75% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.